GLP1R and bacterial urinary tract infection: GLP-1 RA use, including semaglutide, was associated with reduced rates of urinary retention and UTIs in non-diabetic women receiving treatment for OAB, with nearly half the risk of retention (4.9% vs. 8.6%; p = 0.0044), a 4.5% absolute reduction in UTIs, and a better 1-year UTI-free survival (log-rank p = 0.0420) (Table 2).